Clinical Trials Browser

Phase 2/3 × Carcinoma, Ovarian Epithelial × Clear all

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06341907 2024-04-02

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Phase 2/3 Recruiting

Carcinoma, Ovarian Epithelial

NCT01506856 2023-09-15

iPocc

Phase 2/3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01091636 2020-02-17

Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer

Phase 2/3 Completed

Carcinoma, Ovarian Epithelial

NCT00003880 2015-04-16

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00075712 2013-08-12

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2/3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00045461 2013-08-07

Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Phase 2/3 Unknown

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms